医学
痴呆
疾病
重症监护医学
神经影像学
神经科学
生物信息学
阿尔茨海默病
精神科
病理
心理学
生物
作者
Sahil Khan,Kalyani Barve,Maushmi S. Kumar
出处
期刊:Current Neuropharmacology
[Bentham Science]
日期:2020-05-28
卷期号:18 (11): 1106-1125
被引量:395
标识
DOI:10.2174/1570159x18666200528142429
摘要
Background: The only conclusive way to diagnose Alzheimer’s is to carry out brain autopsy of the patient’s brain tissue and ascertain whether the subject had Alzheimer’s or any other form of dementia. However, due to the non-feasibility of such methods, to diagnose and conclude the conditions, medical practitioners use tests that examine a patient’s mental ability. Objective: Accurate diagnosis at an early stage is the need of the hour for initiation of therapy. The cause for most Alzheimer’s cases still remains unknown except where genetic distinctions have been observed. Thus, a standard drug regimen ensues in every Alzheimer’s patient, irrespective of the cause, which may not always be beneficial in halting or reversing the disease progression. To provide a better life to such patients by suppressing existing symptoms, early diagnosis, curative therapy, site-specific delivery of drugs, and application of hyphenated methods like artificial intelligence need to be brought into the main field of Alzheimer’s therapeutics. Methods: In this review, we have compiled existing hypotheses to explain the cause of the disease, and highlighted gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics and quantum dots as advancements in the existing strategies to manage Alzheimer’s. Conclusion: Biomarkers, brain-imaging, and theranostics, along with artificial intelligence, are understood to be the future of the management of Alzheimer’s.
科研通智能强力驱动
Strongly Powered by AbleSci AI